Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: A Phase II Multicenter Study
Collin M. Blakely(City College of San Francisco), David M. Jablons(City College of San Francisco), Greg M. Allen(University of California, San Francisco), Claire K. Mulvey(University of California, San Francisco), Tejas Patil(Sidney Kimmel Comprehensive Cancer Center), Anatoly Urisman(City College of San Francisco), Robert C. Doebele(Aurora University), Lisa Tan(University of California, San Francisco), W. Patrick Devine(Cancer Research Institute), Stephen Shiboski(University of California, San Francisco), Bianca Bacaltos(University of California, San Francisco), Dara L. Aisner(University of Colorado System), Johannes R. Kratz(University of California, San Francisco), Matthew A. Gubens(University of California, San Francisco), Kirk D. Jones, Jacqueline V. Aredo(Stanford University), Erin L. Schenk(University of Colorado Anschutz Medical Campus), Jonathan W. Riess(University of California Davis Medical Center), Turja Chakrabarti(University of California, San Francisco), D. Lucas Kerr(UCSF Helen Diller Family Comprehensive Cancer Center), Melissa H. Coleman(University of California, San Francisco), Trever G. Bivona(University of California, San Francisco), Megan Gee(University of California, San Francisco), Julia Rotow(University of California, San Francisco)
Cited by 65
Related Papers
Oncogenic Signaling Pathways in The Cancer Genome Atlas
|Cell|2018|3.4k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study
|Journal of Clinical Oncology|2019|1.3k
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
|Journal of Clinical Oncology|2021|1.1k